Study to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib and Idelalisib With and Without Obinutuzumab in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

December 13, 2016

Primary Completion Date

June 17, 2019

Study Completion Date

January 14, 2021

Conditions
Chronic Lymphocytic Leukemia
Interventions
DRUG

Tirabrutinib

Tablets administered orally

DRUG

Idelalisib

Tablets administered orally

DRUG

Obinutuzumab

Administered intravenously

Trial Locations (14)

23562

Luebecker Onkologische Schwerpunktpraxis, Lübeck

35392

Internistische Gemeinschaftspraxis Dres. Schliesser-Käbisch-Weber, Gießen, Giessen

41063

KH Maria Hilf-Franziskushaus, Mönchengladbach, Mönchengladbach

50937

Uniklinik Koln, Cologne

60596

Ambulante Krebszentrum Schaubstraße, Frankfurt (Oder)

68167

Universitasmtedizin Mannheim, Mannheim

73557

Stauferklinikum Schwäbisch Gmünd, Mutlangen

80804

Krankenhaus München-Schwabing, München

81675

Klinikum Rechts der Isar der Technischen Universität München, München

86150

Hämatologische-onkologische Gem.-Praxis Dres. Brudler-Heinrich-Bangerter, Augsburg, Augsburg

88212

Studienzentrum Onkologie Ravensburg, Ravensburg

89081

Universitätsklinikum Ulm, Ulm

93053

Facharztzentrum Regensburg, Regensburg

04103

Uniklinik Leipzig, Leipzig

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

German CLL Study Group

OTHER

lead

Gilead Sciences

INDUSTRY

NCT02968563 - Study to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib and Idelalisib With and Without Obinutuzumab in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) | Biotech Hunter | Biotech Hunter